- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company
- Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.
- Merck KGaA and the Church of the Brethren collaborate with several companies, including Integra LifeSciences and Henry Schein, to contribute to a new facility stock.
Coverage
Newest first; wire copies grouped- Unknown outlet